key: cord-0987413-uv7i4zve
authors: Yang, Kai S.; Ma, Xinyu R.; Ma, Yuying; Alugubelli, Yugendar R.; Scott, Danielle A.; Vatansever, Erol C.; Drelich, Aleksandra K.; Sankaran, Banumathi; Geng, Zhi Z.; Blankenship, Lauren R.; Ward, Hannah E.; Sheng, Yan J.; Hsu, Jason C.; Kratch, Kaci C.; Zhao, Baoyu; Hayatshahi, Hamed S.; Liu, Jin; Li, Pingwei; Fierke, Carol A.; Tseng, Chien-Te K.; Xu, Shiqing; Liu, Wenshe Ray
title: A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors
date: 2020-07-28
journal: bioRxiv
DOI: 10.1101/2020.07.28.223784
sha: 7def6236b8c22d48bf70ff03ec9406012ece2a4d
doc_id: 987413
cord_uid: uv7i4zve

The COVID-19 pathogen, SARS-CoV-2, requires its main protease (SC2MPro) to digest two of its translated polypeptides to form a number of mature proteins that are essential for viral replication and pathogenesis. Inhibition of this vital proteolytic process is effective in preventing the virus from replication in infected cells and therefore provides a potential COVID-19 treatment option. Guided by previous medicinal chemistry studies about SARS-CoV-1 main protease (SC1MPro), we have designed and synthesized a series of SC2MPro inhibitors that contain β-(S-2-oxopyrrolidin-3-yl)-alaninal (Opal) for the formation of a reversible covalent bond with the SC2MPro active site cysteine C145. All inhibitors display high potency with IC50 values at or below 100 nM. The most potent compound MPI3 has as an IC50 value as 8.5 nM. Crystallographic analyses of SC2MPro bound to 7 inhibitors indicated both formation of a covalent bond with C145 and structural rearrangement from the apoenzyme to accommodate the inhibitors. Virus inhibition assays revealed that several inhibitors have high potency in inhibiting the SARS-CoV-2-induced cytopathogenic effect in both Vero E6 and A549 cells. Two inhibitors MP5 and MPI8 completely prevented the SARS-CoV-2-induced cytopathogenic effect in Vero E6 cells at 2.5-5 μM and A549 cells at 0.16-0.31 μM. Their virus inhibition potency is much higher than some existing molecules that are under preclinical and clinical investigations for the treatment of COVID-19. Our study indicates that there is a large chemical space that needs to be explored for the development of SC2MPro inhibitors with extreme potency. Due to the urgent matter of the COVID-19 pandemic, MPI5 and MPI8 may be quickly advanced to preclinical and clinical tests for COVID-19.

Coronaviruses (CoVs) are a group of related RNA viruses that cause diseases in a wide range of vertebrates including humans and domestic animals. 1 Before 2003, there were only two CoVs, HCoV-229E and HCoV-OC43, known as human pathogens. 2, 3 The SARS pandemic in 2003 led to the revelation of SARS-CoV-1, a pathogen causing a severe respiratory infection. 4 The subsequent surge in CoV research resulted in the discovery of two additional human CoVs, HCoV-NL63 and HCoV-HKU1, that are mildly pathogenic. 5, 6 One addition to this group was MERS-CoV that emerged in 2012 as a pathogen causing a severe respiratory infection. 7 Although SARS-CoV-1 and MERS-CoV are highly lethal pathogens, the public health, social, and economic damages that they have caused are diminutive in comparison to that from SARS-CoV-2, a newly emerged human CoV pathogen that causes COVID-19. 8 Rival only to the 1918 influenza pandemic, the COVID-19 pandemic has led to catastrophic impacts worldwide. As of July 13 th , 2020, the total global COVID-19 cases have surpassed 12 million with more than 570,000 deaths. 9 To alleviate catastrophic damages of COVID-19 on public health, society and economy, finding timely treatment options is of paramount importance.

Similar to all other CoVs, SARS-CoV-2 is an enveloped, positive-sensed RNA virus with a genome of nearly 30 kb in size. 10 Its genome encodes 10 open reading frames (ORFs). The largest ORF, ORF1ab encompasses more than two thirds of the whole genome. Its translated products, ORF1a (~500 kDa) and ORF1ab (~800 kDa), 11 are very large polypeptides that undergo proteolytic cleavage to form 15 mature proteins. These are nonstructural proteins (Nsps) that are essential for the virus to modulate human cell hosts for efficient viral protein expression, genome replication, virion packaging, viral genome transcription and replication, and viral genomic RNA processing to evade the host immune system. The proteolytic cleavage of ORF1a and ORF1ab is an autocatalytic process. Two internal polypeptide regions, Nsp3 and Nsp5, possess cysteine protease activity that cleaves themselves, and all other Nsps, from the two polypeptides. Nsp3 is commonly referred to as papain-like protease (PL Pro ), and Nsp5 as 3C-like protease (3CL Pro ) or, more recently, main protease (M Pro ). 12 Although we have yet to understand SARS-CoV-2 biology and COVID-19 pathogenesis, previous studies of SARS-CoV-1 have established that activity of both PL Pro and M Pro is essential to viral replication and pathogenesis. Of the two proteases, M Pro processes 12 out of the total 15 Nsps; inhibition of this enzyme is anticipated to have more significant impacts on the viral biology than that of PL Pro . Therefore, small molecule medicines that potently inhibit SARS-CoV-2 M Pro (SC2M Pro ) are potentially effective treatment options for 14, 15 In this work we report our progress in the development of potent SC2M Pro inhibitors.

Although we are at the inaugural stage of learning medicinal chemistry to inhibit SC2M Pro , much has been learned from studies of SARS-CoV-1 M Pro (SC1M Pro ) that shares 96% sequence identity with SC2M Pro . 16 SC1M Pro has a large active site that consists of several smaller pockets for the recognition of residues at P1, P2, P4, and P3' positions in a protein substrate ( Figure 1A ). 17 P4 is typically a small hydrophobic residue while P2 and P3' are large. For all Nsps that are processed by SC1M Pro and SC2M Pro , Gln is the P1 residue at their cleavage sites. In order to bind the P1 Gln, SC1M Pro forms strong van der Waals interactions with the Gln side chain, and also utilizes two hydrogen bonds with the Gln side chain amide oxygen and a-carbonyl oxygen atoms ( Figure 1B ). Previous efforts in the development of irreversible covalent inhibitors for SC1M Pro primarily focused on fixing the P1 residue as a more potent b-S-2-oxopyrrolidine-containing Gln analog, and changing the scissile backbone amide to an alkene Michael acceptor in order to react with the active site cysteine C145, as well as varying substituents on two sides to improve potency. 18 The enhanced potency from the use of the b-S-2-oxopyrrolidine-containing Gln analog is most probably due to the reduction of entropy loss during the binding of SC1M pro to the more rigid lactam compared to the flexible Gln. Although converting the scissile backbone amide to a Michael acceptor in a SC1M Pro ligand turns it into a covalent inhibitor, it eliminates the critical hydrogen bond between the P1 a-carbonyl oxygen and SC1M Pro . Therefore, most Michael acceptor inhibitors developed for SC1M Pro and recently for SC2M Pro tend to have efficacy with low micromolar or submicromolar IC50 values rather than low nanomolar levels. 13, 18 To maintain this critical hydrogen bond and exploit a covalent interaction with the active site cysteine C145 to form a hemiacetal for high affinity, both aldehyde and ketoamide moieties have been used to replace the P1 C-side a-amide to develop potent reversible covalent inhibitors for SC1M Pro . For aldehyde-based inhibitors, a typical potent inhibitor contains Opal at the P1 site that consists of a b-S-2-oxopyrrolidine side chain and an a-aldehyde for both taking advantage of strong interactions with the SC1M Pro P1-binding pocket and the formation of a reversible covalent bond with C145 ( Figure 1C) . Typical examples of this design include GC376 that was originally developed for M Pro from feline infectious peritonitis (FIP) CoV and two inhibitors, 11a and 11b, that were recently developed for SC2M Pro . 19, 20 Given its relative simplicity, we have followed a similar scheme according to structure diagrams shown in Figure 1D to design and synthesize reversible covalent inhibitors for SC2M Pro and pursued structural variations at P2, P3, and R positions for improved potency.

GC376 ( Figure 2A ) has confirmed potency against SC1M Pro . 21 We purchased it as a potential SC2M Pro inhibitor. We designed two similar dipeptidyl compounds MPI1-2 ( Figure 2A ) and synthesized them according to a synthetic scheme shown in Supplementary Scheme 1. Both MPI1 and MPI2 have Phe at the P2 site which was previously shown to contribute to strong bonding to SC1M Pro . 18 MPI2 has also an o-fluoro-p-chlorocinnamyl group as an N-terminal cap. This group is more rigid than the CBZ group and therefore possibly introduces a strong interaction with the P4-binding pocket in SC2M Pro . 22 To characterize IC50 values of all three molecules for inhibition of SC2M Pro , we recombinantly expressed a 6´His-SUMO-SC2M Pro fusion protein in E. coli and purified and digested this protein with SUMO protease to obtain intact SC2M Pro with more than 95% purity. We used a previously described fluorescent peptide assay (see supplementary data) to measure the IC50 values for GC376, MPI1, and MPI2 as 31 ± 4, 100 ± 23, and 103 ± 14 nM, respectively ( Figure 2B ). 15 Our determined IC50 value for GC376 agrees well with that from Ma et al. 23 In the light of the publication of inhibitors 11a and 11b that showed similar IC50 values as 53 ± 5 and 40 ± 2 nM, respectively, 24 we shifted our focus from the synthesis of bipeptidyl inhibitors to that of tripeptidyl inhibitors. By adding one more residue to the design of inhibitors, additional interactions with SC2M Pro might be achieved to improve potency. In the design of SC1M Pro inhibitors, Leu, Phe, and Cha (cyclohexylalanine) are three residues used frequently at the P2 site and Val and Thr(tBu) (O-tert-butyl-threonine) are two residues used frequently at the P3 site. 18 Installation of these residues at two sites and including CBZ as a N-terminal cap led to the design of six compounds MPI3-8 ( Figure 2A ). We added one additional compound MPI9 that has an o-fluoro-p-chlorocinnamyl cap to this series to compare the effect of the two N-terminal caps on the inhibitor potency for SC2M Pro . We synthesized all 7 compounds according to a synthetic scheme presented in Supplementary Scheme 2 and characterized their IC50 values using the fluorescent peptide assay. As shown in Figure 2B , all inhibitors have IC50 values below 100 nM, except for MPI8 that has an IC50 value as 105 ± 22 nM. The most potent compound is MPI3 with an IC50 value as 8.5 ± 1.5 nM, followed by MPI4 and MPI5 with IC50 values as 15 ± 5 and 33 ± 2 nM, respectively. We also synthesized 11a (named as MPI10 in our series) according to the procedure in Dai et al. and used it as a positive control in our enzyme and viral inhibition analyses. 24 Using our fluorescent peptide assay, we determined the IC50 value of 11a as 31 ± 3 nM.

As far as we know, MPI3 is the most potent SC2M Pro inhibitor that has been reported so far. From the perspective of enzyme inhibition, Leu and Val are optimal residues at P2 and P3 sites in an inhibitor for improved affinity for SC2M Pro and CBZ also enhances affinity compared to the ofluoro-p-chlorocinnamyl as a N-terminal capping group.

In order to understand how our designed inhibitors interact with SC2M Pro at its active site, we screened crystallization conditions for apo-SC2M Pro , soaked apo-SC2M Pro crystals with different inhibitors, and determined the crystal structures of these inhibitors in complex with SC2M Pro . We used Hampton Research Crystal Screen and Index kits to perform initial screening and identified several conditions that yielded single crystals of apo-SC2M Pro . For all conditions, crystals were in a thin plate shape (Supplementary Figure S1 ). The best crystallization condition contained 0.2 M dibasic ammonium phosphate and 17% PEG 3,350. We refined the structure of apo-SC2M Pro against diffraction data to 2.0 Å resolution. In the apoenzyme crystals, SC2M Pro existed as a monomer in the crystallographic asymmetric unit and packed relatively densely. The active site of each monomer stacked upon another monomer (two representative monomers are shown in red and blue respectively in Figure 3A ). This close contact and dense protein packing made the diffusion of inhibitors to the active site quite slow. We soaked apo SC2M Pro crystals with all 9 inhibitors that we synthesized and collected and processed their X-ray diffraction data for structural determination. For crystals that we soaked with the inhibitors for just 2 h, we did not find observable ligand electron density at the enzyme active site. For 7 inhibitors including MPI1 and MPI3-8, we performed two-day soaking and observed clear electron density in the difference maps in the active site of the enzyme. For MPI2 and MPI9, we were not able to determine structures of their complexes with SC2M Pro due to cracking of the crystals upon soaking with the inhibitors. For MPI3, the electron density around the P1, P2, and P3 residues were well defined, and the covalent interaction between the C145 side chain thiolate and the Opal aldehyde to form a hemiacetal was clearly observable ( Figure 3B ). The electron density around CBZ was very weak indicating flexible CBZ binding around the enzyme P4-binding pocket. Figure 3C interactions with the P2 Leu in MPI3. We observe Leu as the best residue in this position probably due to this close van der Waals interaction range for the recognition of the P2 Leu side chain. The enzyme has no P3-binding pocket. However, the P3 Val in MPI3 positions its side chain in van der Waals interaction distance to E166 and P168. In the structure, CBZ narrowly fits into the P4-binding pocket and the channel formed between the P168-and Q192-containing loops. The P168 loop rearranges its position from that in apoenzyme to accommodate the CBZ group. The CBZ group also has weak electron density. These observations indicate that CBZ is not an optimal structural moiety for interaction at these sites. Besides interactions involving side chains and the Table S1 ). The structural superposition of all seven inhibitor complexes with SC2M Pro show a similar binding mode for all inhibitors to the SC2M Pro active site ( Figure 4F ). The electron density around the CBZ group for all inhibitors is not well defined. Some inhibitorenzyme complex structures have relatively weak electron density at P2 and P3 residues in their inhibitors possibly due to low occupancy or flexible conformations at these positions.

To evaluate our molecules' ability to inhibit SARS-CoV-2, we conducted a live virus-based microneutralization assay in Vero E6 cells. Vero E6 is a kidney epithelial cell line isolated from African Green Monkey. It has been used widely as a model system for human CoV studies. 25 We tested 10 molecules including GC376, MPI1-8, and 11a in a concentration range from 80 nM to 10 µM and recorded cytopathogenic effect (CPE) observed in SARS-CoV-2-infected Vero E6 cells that we cultured in the presence of different concentrations of inhibitors. 11a was included as a positive control. For each condition, we conducted two repeats. Although it was disappointing that MPI3 was not able to completely prevent CPE at all tested concentrations, several inhibitors abolished CPE: GC376, MPI2, MPI6, and 11a at 10 µM, MPI5 at 5 µM, MPI7 at 2.5-5 µM, and MPI8 at 2.5 µM ( Figure 4A ). Three compounds MPI5, MPI7 and MPI8 performed better than GC376 that has been recently explored by Anivive Lifesciences for the treatment of COVID-19 and 11a that has been considered for COVID-19 clinical studies. 15 Since we only recorded complete abolition of CPE, the real EC50 values for these compounds are expected to be much lower than lowest observed concentrations for CPE abolishment. Encouraged by our results in

Vero E6 cells, we tested the three most potent compounds MPI5, MPI7, and MPI8 and also 11a in A549 cells. The A549 cell line was derived from human alveolar epithelial cells. It mimics the SARS-CoV-2 infection of the human respiratory tract system better than Vero E6. 26 We tested a same concentration range for all four compounds. MPI7 was not able to completely abolish CPE at all tested conditions. However, both MPI5 and MPI8 performed much better than in Vero E6 cells with complete abolition of CPE at 160-310 nM and much better than 11a ( Figure 4B ). 11 displayed potency similar to that shown in Vero E6 cells. Given that real EC50 values are expected to be lower than the lowest observed concentration for CPE abolishment, MPI5 and MPI8 are, as far as we know, the most potent anti-SARS-CoV-2 small molecules in infected cells that have been reported so far.

Guided by previous medicinal chemistry studies about SC1M Pro , we designed and synthesized a number of Opal-based dipeptidyl and tripeptidyl inhibitors that potently inhibit SC2M Pro , an essential enzyme for SARS-CoV-2, the pathogen of COVID-19. As the most potent inhibitor of SC2M Pro , MPI3 displayed an IC50 value of 8.5 nM. As far as we know, this is the lowest reported IC50 for known SC2M Pro inhibitors. During the search of optimal conditions for IC50 characterizations, we noticed that 10 nM was the lowest SC2M Pro concentration that could provide reliable activity. 15 Since the determined IC50 value for MPI3 is lower than the used enzyme concentration, the real Kd value of MPI3 is expected to be much lower than 8.5 nM. X-ray crystallography analysis of the SC2M Pro -MPI3 complex revealed that MPI3 fits precisely in the P1-and P2-binding pockets at the SC2M Pro active site. Strong van der Waals interactions at the P1-and P2-binding pockets, 9 hydrogen bonds with active site residues, and the covalent interaction with C145 necessitate high affinity of MPI3 to SC2M Pro . The structures of SC2M Pro complexes with MPI3 and other inhibitors showed a relatively loosely bound N-terminal capping group. We expect that optimization at this site will contribute to the generation of more potent inhibitors in the future. Although MPI3 is the most potent inhibitor for the enzyme, its cellular activity in inhibiting SARS-CoV-2 is much lower than several other inhibitors we have generated.

A likely reason is its lower cellular stability. MPI3 has Leu and Val at its P2 and P3 sites respectively. Both are native amino acids that are expected to be targeted by both extracellular and cellular proteases. Since Leu and Val are optimal residues at two sites, modest changes based on these structures will be necessary for both maintaining high potency in inhibiting SC2M Pro and improving cellular stability for enhanced cellular activity in inhibiting the virus. As such, Val and Leu analogs at these two sites need to be explored. Since both MPI5 and MPI8 show high anti-SARS-CoV-2 activity in both Vero E6 and A549 cells and each has Cha at their P2 site, we suggest maintaining Opal and Cha at P1 and P2 sites and varying the residue at P3 and the N-terminal capping moiety to improve anti-SARS-CoV-2 activity in cells. Based on our structures of SC2M Pro complexes with 7 inhibitors, the P1 Opal occupies precisely the P1-binding pocket in SC2M Pro and three hydrogen bonds to the Opal lactam amide are critical in maintaining strong binding to SC2M Pro . Chemical space to manipulate the P1 residue in an inhibitor for improved binding to SC2M Pro is minimal. But one direction that may be explored is to introduce additional heteroatom(s) to Opal for the formation of hydrogen bond(s) with the N142 side chain amide. In the SC2M Pro -MPI3 complex, the N142 side chain flips by about 180º from its position in apoenzyme to form a closed P1-binding pocket. However, only van der Waals interactions with Opal are involved with N142. Given the close distance between the Opal side chain and the side chain amide of N142, some hydrogen bonds may be designed for improved potency. In all our designed inhibitors, an Opal aldehyde is involved in the formation of a covalent interaction with C145. This design, although necessary for the formation of a hemiacetal covalent complex, effectively excludes the exploration of the P3'-binding site in SC2M Pro for improved potency in a designed inhibitor. Figure 4D illustrates that the P3'-binding pocket is completely empty. In our early discussion, we argued that it is critical to maintain the hydrogen bond between the scissile amide oxygen in a substrate and SC2M Pro for high affinity. Changing the scissile amide to an aldehyde in an inhibitor is effective in maintaining this hydrogen bond and allows a covalent interaction with C145. Two hydrogen bonds formed between the hemiacetal alcohol and SC2M Pro contribute to high potency of this group of molecules. One possibility to keep all of these described potentials that are associated with the Opal aldehyde in an inhibitor but to reach out to the P3'binding site for even stronger binding to SC2M Pro is to convert the aldehyde to an a-ketoamide.

Lower reactivity of a-ketoamide in comparison to aldehyde toward C145 to generate a hemiacetal might be compensated and surpassed by adding chemical moieties to the a-ketoamide for strong interactions with the P3'-binding pocket. All these possibilities are worth exploring.

In our study, cell-based anti-SARS-CoV-2 activity of our designed inhibitors do not correlate with their IC50 values in inhibiting SC2M Pro . This is expected since cellular stability and other features of these inhibitors are very different. However, information regarding both enzyme inhibition IC50 values and anti-SARS-CoV-2 activity is critical for the design of a new generation of inhibitors that perform excellent in both aspects. Given that MPI3 has already reached a single digit nanomolar IC50 value and MPI5 and MPI8 display high potency in inhibiting SARS-CoV-2, merging features of the three molecules will lead to inhibitors with extreme potency in inhibiting the virus. Our antiviral assays indicated that MPI5 and MPI8 performed much better than GC376 and 11a, two molecules that have been explored for COVID-19 preclinical and clinical tests. Due to the urgent matter of COVID-19, we urge preclinical and clinical tests of both MPI5 and MPI8

in the treatment of COVID-19 and are actively exploring them. 

Commentary: Origin and evolution of pathogenic coronaviruses

Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease

A new virus isolated from the human respiratory tract

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Identification of a new human coronavirus

Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia

Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic

World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)

COVID-19 pandemic

Genomic characterization of a novel SARS-CoV-2

Genetic diversity and evolution of SARS-CoV-2

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates

Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

Targeting the SARS-CoV-2 Main Protease to Repurpose Drugs for COVID-19

Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV

protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity

An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy

Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Broadspectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses

Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors

GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Proliferative growth of SARS coronavirus in Vero E6 cells

Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro

Liu and grant R01AI145287 to P. Li) and Welch Foundation (grant A-1715 to W.R. Liu and grant A-1987 to C. A. Fierke). We are grateful to Prof. Thomas Meek for allowing us to use the LC-MS system in his group for purification and characterization of some of our compounds. The ALS-ENABLE beamlines are

National Institute of General Medical Sciences, grant P30 GM124169-01 and the Howard Hughes Medical Institute. The Advanced Light Source is a Department of Energy Office of Science User Facility under Contract No

The authors declare no competing financial interests.

Please see the associated Supplementary Materials for details about compound synthesis, protein expression, inhibition characterization, X-ray crystallography analysis, virus microneutralization assays, Nuclear magnetic resonance and mass spectrometry characterization of synthesized compounds and related spectra, X-ray data collection and structure refinement data